MK-8591A
Total Payments
$7.9M
Transactions
2,598
Doctors
40
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $7.4M | 2,546 | 36 |
| 2019 | $79,270 | 47 | 6 |
| 2018 | $331,150 | 5 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $7.8M | 2,225 | 98.8% |
| Consulting Fee | $46,689 | 35 | 0.6% |
| Travel and Lodging | $37,566 | 158 | 0.5% |
| Food and Beverage | $10,886 | 179 | 0.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $75.00 | 1 | 0.0% |
Payments by Type
Research
$7.8M
2,225 transactions
General
$95,216
373 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 3, Randomized, Active-Controlled, Double-blind Clinical Study to Evaluate a Switch to Doravirine,Islatravir DOR,ISL Once-Daily in Participants With HIV-1 Virologically Suppressed on Bictegravir,Emtricitabine,Tenofovir Alafenamide BIC,FTC,TAF | Merck Sharp & Dohme Corporation | $3.9M | 0 |
| A Phase 3, Randomized, Active-Controlled, Open-label Clinical Study to Evaluate a Switch to Doravirine,Islatravir DOR,ISL Once-Daily in Participants With HIV-1 Virologically Suppressed on Antiretroviral Therapy | Merck Sharp & Dohme Corporation | $1.4M | 0 |
| Phase 3 Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Antiretroviral Activity, Safety, and Tolerability of Doravirine,Islatravir Once-Daily in HIV-1 Infected Treatment-Na ve Participants | Merck Sharp & Dohme Corporation | $1.1M | 0 |
| An Open-Label Clinical Trial to Evaluate the Pharmacokinetics and Relative Bioavailability of Three Experimental Presentations of the Fixed Dosed Combination of Doravirine,Islatravir MK-8591A in Healthy Participants | Merck Sharp & Dohme Corporation | $657,525 | 0 |
| An Open-Label Clinical Trial to Evaluate the Pharmacokinetics and RelativeBioavailability of Two Formulations of MK-8591A and the Effect of a Proton Pump Inhibitor on the Pharmacokinetics of MK-8951A in Healthy Participants | Merck Sharp & Dohme Corporation | $345,333 | 0 |
| A Phase 3, Randomized, Clinical Study in HIV-1-Infected Heavily Treatment-Experienced Participants Evaluating the Antiretroviral Activity of Blinded Islatravir ISL, Doravirine DOR, and Doravirine,Islatravir DOR,ISL, Each Compared to Placebo, and the Antiretroviral Activity, Safety, and Tolerability of Open-Label DOR,ISL. | Merck Sharp & Dohme Corporation | $202,283 | 0 |
| A Phase 2 Clinical Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Doravirine,Islatravir in Pediatric Participants with HIV-1 Infection who are Virologically Suppressed or Treatment-Na ve, are Less Than 18 Years of Age, and Weigh Greater Than or Equal to 35 kg | Merck Sharp & Dohme Corporation | $52,505 | 0 |
| A Phase 2B, Randomized, Double-Blind, Active-Comparator-Controlled, Dose-Ranging Clinical Trial to Evaluate the Safety, Tolerability, Antiretroviral-Activity, and Pharmacokinetics of MK 8591 Given in Combination with Doravirine DOR and Lamivudine 3TC in HIV-1-Infected Treatment-Na ve Adults | Merck Sharp & Dohme Corporation | $4,311 | 0 |
| A Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral MK-8591 Once-Monthly in Participants at Low-Risk for HIV-1 Infection | Merck Sharp & Dohme Corporation | $138.93 | 0 |
Top Doctors Receiving Payments for MK-8591A — Page 2
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Infectious Disease | Washington, DC | $1,332 | 12 |
| , MD | Infectious Disease | Fort Pierce, FL | $1,331 | 10 |
| Anthony Scarsella | — | Beverly Hills, CA | $1,263 | 7 |
| , M.D | Infectious Disease | Fort Worth, TX | $1,234 | 10 |
| Tanya Schreibman | — | Sarasota, FL | $1,214 | 1 |
| , MD | Infectious Disease | Bronx, NY | $1,128 | 11 |
| , MD | Internal Medicine | Miami Beach, FL | $1,104 | 8 |
| , D.O | Geriatric Medicine | Phoenix, AZ | $989.68 | 9 |
| , M.D | Infectious Disease | Sacramento, CA | $945.28 | 9 |
| , M.D | Infectious Disease | Sacramento, CA | $896.27 | 10 |
| , MD | Diagnostic Radiology | Big Spring, TX | $884.73 | 9 |
| , M.D | Internal Medicine | Hialeah, FL | $860.17 | 7 |
| , MD | Internal Medicine | San Francisco, CA | $784.57 | 8 |
| , MD | Internal Medicine | Los Angeles, CA | $666.23 | 6 |
| , MD | Infectious Disease | Palm Springs, CA | $529.38 | 5 |
| , M.D | Infectious Disease | Baltimore, MD | $468.75 | 1 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $7.9M
- Total Doctors 40
- Transactions 2,598
About MK-8591A
MK-8591A is a drug associated with $7.9M in payments to 40 healthcare providers, recorded across 2,598 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2018 to 2020. In 2020, $7.4M was paid across 2,546 transactions to 36 doctors.
The most common payment nature for MK-8591A is "Unspecified" ($7.8M, 98.8% of total).
MK-8591A is associated with 9 research studies, including "A Phase 3, Randomized, Active-Controlled, Double-blind Clinical Study to Evaluate a Switch to Doravirine,Islatravir DOR,ISL Once-Daily in Participants With HIV-1 Virologically Suppressed on Bictegravir,Emtricitabine,Tenofovir Alafenamide BIC,FTC,TAF" ($3.9M).